Contact

Coronavirus disease 2019 (COVID-19) pandemic is caused by SARS-CoV-2 (SARS2, 2019-nCoV) infection, a newly emerged novel coronavirus spreading worldwide. Current efforts are focusing on development of specific antiviral drugs. Therapeutic neutralizing antibodies (NAbs) against SARS-CoV-2(SARS2, 2019-nCoV) will be greatly important therapeutic agents for the treatment of COVID-19. The availability of therapeutic NAbs against SARS-CoV-2 will offer benefits for the control of the current pandemic and the possible re-emergence of the virus in the future, and their development therefore remains a high priority.

GeneMedi's NAbs has been validated to reduce SARS-CoV-2 lentivirus-based pseudo virus infectivity and thereby blocking the entry of the Coronavirus to its effector/targeting cell: human ACE2-HEK293T cell.

GeneMedi's NAbs has been validated by
   1. COVID-19 Spike protein and Spike-RBD protein binding affnity. Click here to Spike-RBD(GMP-V-2019nCoV-SRBD001)
   2. 2019nCoV pseudotyped virus (PSV) based neutralization assay in 293T-ACE2 effector cell. Click here to SARS-CoV-2 Pseudotyped virus
   3. Competitively blocking the binding of ACE-2 receptor with SARS-CoV-2 Spike protein. Click here to ACE2-Fc(GMP-H-ACE2002)SRBD001、 S1S2001

GeneMedi's Coronavirus neutralizing antibodies (Nabs) can either act as positive control in COVID-19 related vaccines and neutralizing antibodies discovery and development, or act as a benchmark in SARS-CoV-2 neutralization potency assay.

GeneMedi's validated COVID-19 neutralizing antibodies group including:
GMP-V-2019nCoV-SnAb001(human IgG1),
GMP-V-2019nCoV-SnAb002(human IgM),
GMP-V-2019nCoV-SnAb003(human IGA),
GMP-V-2019nCoV-SnAb004(mouse IgG1),
GMP-V-2019nCoV-SnAb005(Cynomolgus (Non human primate, NHP) IgG1).



Potency Validated COVID-19 SARS-CoV-2 neutralizing antibody


Cat No. Antigen Name of 2019-nCoV(SARS-CoV-2) Source
(Expression Host)
Isotypes Bioactivity validation Order
GMP-V-2019nCoV-SnAb001Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgG1)Mammalian (human cell)human IgG1Validated in COVID-19 Spike protein and Spike-RBD protein binding affnity.
COVID-19 related neutralizing potency is validated by
1.2019nCoV pseudotyped virus based neutralization assay in 293T-ACE2 effector cell.
2. competitively blocking the binding of ACE-2 receptor with SARS-CoV-2 Spike protein.
Picture loading failed.
GMP-V-2019nCoV-SnAb002Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgM)Mammalian (human cell)human IgMValidated in COVID-19 Spike protein and Spike-RBD protein binding affnity.
COVID-19 related neutralizing potency is validated by
1.2019nCoV pseudotyped virus based neutralization assay in 293T-ACE2 effector cell.
2. competitively blocking the binding of ACE-2 receptor with SARS-CoV-2 Spike protein.
Picture loading failed.
GMP-V-2019nCoV-SnAb003Anti-2019-nCoV Spike (Spike RBD domain) human monoclonal neutralizing antibody (IgA)Mammalian (human cell)human IgAValidated in COVID-19 Spike protein and Spike-RBD protein binding affnity.
COVID-19 related neutralizing potency is validated by
1.2019nCoV pseudotyped virus based neutralization assay in 293T-ACE2 effector cell.
2. competitively blocking the binding of ACE-2 receptor with SARS-CoV-2 Spike protein.
Picture loading failed.
GMP-V-2019nCoV-SnAb004Anti-2019-nCoV Spike (Spike RBD domain) mouse monoclonal neutralizing antibody (IgG1)Mammalian (human cell)mouse IgG1Validated in COVID-19 Spike protein and Spike-RBD protein binding affnity.
COVID-19 related neutralizing potency is validated by
1.2019nCoV pseudotyped virus based neutralization assay in 293T-ACE2 effector cell.
2. competitively blocking the binding of ACE-2 receptor with SARS-CoV-2 Spike protein.
Picture loading failed.
GMP-V-2019nCoV-SnAb005Anti-2019-nCoV Spike (Spike RBD domain) Cynomolgus monoclonal neutralizing antibody (IgG1)Mammalian (human cell)Cynomolgus (Non human primate, NHP) IgG1Validated in COVID-19 Spike protein and Spike-RBD protein binding affnity.
COVID-19 related neutralizing potency is validated by
1.2019nCoV pseudotyped virus based neutralization assay in 293T-ACE2 effector cell.
2. competitively blocking the binding of ACE-2 receptor with SARS-CoV-2 Spike protein.
Picture loading failed.


Related Products

Pseudotyped virus of SARS-CoV-2 Spike Mutation Variants and Effector cells


2019 nCoV (SARS2 coronavirus) Antibodies for COVID-19

Cat No. Products Name Host specics Source (Expression Host) Bioactivity validation Order
GMP-V-2019nCoV-NAb001 Anti-2019-nCoV NP human monoclonal antibody human
IgG
Mammalian
(human cell)
N protein binding, ELISA validated as capture antibody and detection antibody.
Pair recommendation with GMP-V-2019nCoV-NAb002 , GMP-V-2019nCoV-NAb003 , GMP-V-2019nCoV-NAb004.
Picture loading failed.
GMP-V-2019nCoV-NAb002 Anti-2019-nCoV NP human
scFv-Fc antibody
Scfv Mammalian
(human cell)
N protein binding, ELISA validated as capture antibody and detection antibody.
Pair recommendation with GMP-V-2019nCoV-NAb001, GMP-V-2019nCoV-NAb003 , GMP-V-2019nCoV-NAb004.
Picture loading failed.
GMP-V-2019nCoV-NAb003 Anti-2019-nCoV NP mouse monoclonal antibody(mAb) Mouse
IgG
Hybridoma N protein binding, ELISA validated as capture antibody and detection antibody.
Pair recommendation with GMP-V-2019nCoV-NAb001, GMP-V-2019nCoV-NAb002, GMP-V-2019nCoV-NAb004.
Picture loading failed.
GMP-V-2019nCoV-NAb004 Anti-2019-nCoV NP mouse monoclonal antibody(mAb) Mouse
IgG
Hybridoma N protein binding, ELISA validated as capture antibody and detection antibody.
Pair recommendation with GMP-V-2019nCoV-NAb001, GMP-V-2019nCoV-NAb002 , GMP-V-2019nCoV-NAb003.
Picture loading failed.
GMP-V-2019nCoV-S1Ab001 Anti-2019-nCoV Spike (S1 protein) human monoclonal antibody human
IgG
Mammalian
(human cell)
S-RBD protein binding, ELISA validated Picture loading failed.
GMP-V-2019nCoV-S1Ab002 Anti-2019-nCoV Spike (S1 protein) human monoclonal antibody human
IgG
Mammalian
(human cell)
S-RBD protein binding, ELISA validated, Western Blot validated Picture loading failed.
GMP-V-2019nCoV-S1Ab003 Anti-2019-nCoV Spike (S1 protein) mouse monoclonal antibody (mAb) Mouse
IgG
Hybridoma S-RBD protein binding, ELISA validated Picture loading failed.
GMP-V-2019nCoV-S1Ab004 Anti-2019-nCoV Spike (S1 protein) mouse monoclonal antibody (mAb) Mouse
IgG
Hybridoma S-RBD protein binding, ELISA validated Picture loading failed.
GMP-h-IL6-Ab01Anti-human IL-6 mouse monoclonal antibody(mAb)Mouse IgGHybridomahuman IL-6 protein binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with GMP-h-IL6Ab02, GMP-h-IL6Ab03 in IL-6 level test and inflammation and cytokine release syndrome (CRS) evaluation.Picture loading failed.
GMP-h-IL6-Ab02Anti-human IL-6 mouse monoclonal antibody(mAb)Mouse IgGHybridomahuman IL-6 protein binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with GMP-h-IL6Ab01,GMP-h-IL6Ab03 in IL-6 level test and inflammation and cytokine release syndrome (CRS) evaluation.Picture loading failed.
GMP-h-IL6-Ab03Anti-human IL-6 mouse monoclonal antibody(mAb)Mouse IgGHybridomahuman IL-6 protein binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with GMP-h-IL6Ab01,GMP-h-IL6Ab02 in IL-6 level test and inflammation and cytokine release syndrome (CRS) evaluation.Picture loading failed.


Protocol of SARS-CoV-2 Pseudovirus (PSV)-Based Neutralization Assay For Vaccines, therapeutic antibodies, peptides and compounds against COVID-19         pdf downloadProtocol Download


SARS-CoV-2 (2019nCoV) pseudotype virus (pseudovirus, PSV) for COVID-19 related vaccines and neutralizing antibodies evaluation.

The outbreak of COVID-19, caused by SARS-CoV-2 (2019-nCoV), has been a global public health threat and caught the worldwide concern. Due to its high pathogenicity and infectivity1, live SARS-CoV-2 should be handled under biosafety level 3 (BSL-3) conditions. GeneMedi has developed SARS-CoV-2 pseudovirus production system, from which the SARS-CoV-2 pseudotyped virus can be handled in biosafety level 2 (BSL-2)2.

GeneMedi's SARS-CoV-2 (2019nCoV) pseudotype virus (pseudovirus, PSV) based neutralization assay is a standard evaluation procedure for COVID-19 related vaccines and neutralizing antibodies potency evaluation. GeneMedi's SARS-CoV-2 PSV is the core ingredient of diagnostics for neutralization serology after vaccinotherapy.

GeneMedi's SARS-CoV-2 pseudotyped virus includes wildtype and the spike mutation variants (D614G, S943P, V367F, G476S, V483A, H49Y, Q239K, A831V, P1263L, D839Y/N/E: D839Y, D839N, D839E). The GeneMedi's SARS-CoV2 PSV panel help for all-in-one vaccinotherapy evaluation.



Application-SARS-CoV-2(2019nCoV) Pseudotyped Virus Based Neutralization Assay3


In the Pseudovirus-Based Neutralization Assay (PBNA), the inhibition of viral entry into cells by neutralizing antibodies is correlated to the decreased levels of firefly luciferase signals in the ACE2 expression cells (hACE2-HEK293T, Cat. GM-SC-293T-hACE201) .

GeneMedi’s Pseudovirus Based Neutralization Assay (PBNA) is a conventional assay method that is suitable for High-Throughout Screening (HTS) without live virus engaged. The Pseudovirus Based Neutralization Assay can be used for evaluating:

1) Neutralizing antibodies (NAbs)3,4
2) Peptides blockers5,6 (peptide inhibitors) or protein7,8
3) Types of Vaccines (Immunized serum)9
4) Compounds targeting Spike induced cell-fusion10.

Protocol of SARS-CoV-2 Pseudovirus (PSV)-Based Neutralization Assay


Materials
1. SARS-CoV-2 Pseudovirus-RFP-fLuciferase (GM-2019nCoV-PSV01)
2. Efforter cell: Alternative
A. hACE2-HEK293T stable cell line (GM-SC-293T-hACE2-01)
B. Wildtype HEK293T cell line, hACE2 vector for transfection (GMV-V-2019nCoV-041)

Protocol

If your efforter cell is hACE2-HEK293T stable cell line, please begin in Step 2.

1.Transfect HEK293T with hACE2-GFP vector (GMV-V-2019nCoV-041) 24hrs before planting the cell into 96-well.

2.Plant the hACE2-HEK293T into 96-well (5,000~10,000 per well) overnight before SARS-CoV-2 PSV infection.

3.Generation of 100ul PSV-Sample mixture:

100ul PSV-Sample mixture Volume
GM-2019nCoV-PSV01*50ul or 5ul
Sample(NAbs, peptides, serum, etc)flexible (According to your own products)
Totaladd culture medium to 100ul
* For GM-2019nCoV-PSV01-1, add 50ul in recommendation (range from20ul~100ul).
For GM-2019nCoV-PSV01-2, add 5ul in recommendation. (range from2ul~10ul).

Incubate PSV-Sample mixture for 1h at room temperature.

4.Remove the medium of efforter cell in 96-well, add 100ul PSV-Sample mixture to 96well cells for infection. 3wells for a group.

5.Fluorescence imaging (RFP) 72hrs after SARS-CoV-2 PSV infection. The firefly luciferase reporter is measured by following the Promega Luciferase Assay Reagent manual.

Tips


If your samples are serum
A standard curve should be generated using serially diluted Nabs (neutralizing antibodies) as a positive control.

If your samples are therapeutic antibodies or peptides candidates
Dilute the samples into concentration gradient for IC50 value evaluation.



GeneMedi SARS-CoV-2 Pseudovirus (PSV) Based Cell Entry

pdf downloadData Post Download

Picture loading failed.


Picture loading failed.

Picture loading failed.

Figure. GeneMedi-SARS-CoV-2 Pseudovirus (PSV) Based Cell Entry validation with fluorescence(A), Luciferase activity (B) and FACS (C) after 72 hours of HEK293T infection. hACE2 significantly enhanced the infection efficiency of the SARS-CoV-2 PSV.

GeneMedi SARS-CoV-2 PSV-Luciferase (Cat.GM-2019nCoV-PSV01) is recombinant pseudotyped lentiviral particles containing SARS-CoV-2 spike protein to mimic SARS-CoV-2 (2019nCoV) cell infection.

GM-2019nCoV-PSV01 is a powerful tool for SARS-CoV-2 related vaccine efficacy evaluation, neutralizing antibodies, peptides blockers competitors neutralization assay, and tissue-specific infection determination.



References

1 XiaolongCai. An Insight of comparison between COVID-19 (2019-nCoV) and SARS-CoV in pathology and pathogenesis. Preprint, doi:10.31219/osf.io/hw34x (2020, paper of GeneMedi).

2 Jean K. Millet1, Tiffany Tang3, Lakshmi Nathan3, Javier A. Jaimes4, Hung-Lun Hsu3,5, & Susan Daniel3, G. R. W. Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting. J Vis Exp, doi:10.3791/59010 (2019).

3 Nie, J. et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg Microbes Infect 9, 680-686, doi:10.1080/22221751.2020.1743767 (2020).

4 Jiang, S., Hillyer, C. & Du, L. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses. Trends Immunol, doi:10.1016/j.it.2020.03.007 (2020).

5 Zhang, G., Pomplun, S., Loftis, A. R., Loas, A. & Pentelute, B. L. The first-in-class peptide binder to the SARS-CoV-2 spike protein. doi:10.1101/2020.03.19.999318 (2020).

6 Xia, S. et al. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res 30, 343-355, doi:10.1038/s41422-020-0305-x (2020).

7 Monteil, V. et al. Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2. Cell, doi:10.1016/j.cell.2020.04.004 (2020).

8 Lei, C. et al. Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig. Nat Commun 11, 2070, doi:10.1038/s41467-020-16048-4 (2020).

9 HuajunBai, X., XiaolongCai. Vaccines And Advanced Vaccines: -A landscape for advanced vaccine technology against infectious disease ,COVID-19 and tumor. Preprint, doi:10.31219/osf.io/ypgx4 (2020).

10 Hoffmann, M. et al. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv, doi:10.1101/2020.01.31.929042 (2020).




GENEMEDI
6th Floor, Buiding No.2, Kangxin Road 3377, Shanghai, China
Email: [email protected] [email protected]
Telephone: +86-21-50478399   Fax: 86-21-50478399
Privacy Policy
Chinese Website

COVID-19
related
protocols,
data and
products

COVID-19 related protocols, data and products

×